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Abstract 38 
Aims: To determine the relative significance of radiological signs in determining the 39 
resectability of peri-ampullary cancer (PC) and to assess the value of multi-phase imaging in 40 
detecting these findings. 41 
Materials and Methods: Blinded, double re-reporting of pre-operative imaging from five 42 
hospitals was undertaken of 411 patients undergoing surgery for PC over an eight year 43 
period, of whom 119 patients were found to be inoperable at the time of surgery. 44 
Results: The median tumour size was 26.7 mm and the proportion of patients reported to have 45 
regional lymphadenopathy (RL), venous (VI) and arterial involvement (AI) was 24.7%, 46 
11.5% and 3.9% respectively and was similar regardless of the number of contrast phases 47 
undertaken. Significant associations were however noted between individual risk factors: VI 48 
was closely associated with tumour size (p=0.002) and AI (p< 0.0001). In multi-variable 49 
analysis AI, VI and RL were independently associated with resectability (relative risk of 50 
resection =0.05, 0.31 and 0.51 respectively). Tumour size however was not associated with 51 
resectability when VI was included in the multivariate model.  52 
Conclusions: The use of multiple vascular contrast phases has no measureable impact on the 53 
rate of determination of tumour resectability of PC. In pre-operative staging AI is the most 54 
significant adverse finding for resectability. Large tumour diameter is not an adverse finding 55 
in isolation from other risk factors.  56 
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Abbreviations and acronyms 63 
AI: Arterial involvement  64 
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RL: Regional lymphadenopathy  66 
VI: Venous involvement 67 
68 
Introduction 69 
Determination of tumour resectability is a major aspect of the interpretation of pre-operative 70 
imaging of peri-ampullary cancer (PC). The findings of distant metastases and local invasion 71 
resulting in occlusion of major arteries or veins are contraindications to attempted surgical 72 
resection, whereas lesser degrees of arterial involvement (AI) and venous involvement (VI), 73 
including abutment and tapering, are relative contraindications, as imaging can sometimes be 74 
inaccurate in determining these findings (1-4), and vein resection can be undertaken where 75 
incomplete venous occlusion is noted (5-7). Tumour size (8) and regional lymphadenopathy 76 
(RL) (9, 10) have also been shown to be associated with unresectability, although RL is a 77 
relative contraindication as these nodes are removed as part of a Whipple procedure (11). 78 
This finding may however be a surrogate marker of an aggressive malignancy, which will 79 
progress rapidly to become inoperable. 80 
Despite pre-operative imaging to exclude patients with contraindications to surgery a 81 
proportion of patients with PC proceeding to operation are found to be inoperable, either due 82 
to unresectable invasion of vascular structures or the presence of metastatic disease. This may 83 
result from either understaging by CT or rapid tumour progression in the interval between 84 
imaging and surgery.  85 
Pre-operative staging of PC is commonly undertaken by contrast-enhanced CT scan. Some 86 
authorities recommend tri-phasic imaging (12), including pre-contrast phase, arterial phase 87 
and portal phase, although the benefits of this over monophasic scans (portal venous phase 88 
only) and biphasic scans (arterial and portal phases) have not been demonstrated. This has 89 
implications in terms of radiation exposure and resource utilisation. There have also been 90 
major improvements in CT scan technology in recent years with the development of multi-91 
detector imaging (13), which would be expected to lead to a reduction in the proportion of 92 
false negative findings, and may have reduced the need for multi-phase imaging. 93 
The principal study aim is to determine a hierarchy of radiological findings in predicting the 94 
resectability of PC in patients undergoing surgery at a regional centre within a Cancer 95 
Network serving five hospitals (A-E) and to investigate the cause of unresectability (local 96 
invasion or metastatic disease) associated with these findings. Secondary aims were to 97 
explore the effect of varied imaging protocols in the detection of these findings to determine 98 
potential advantages of multi-phase imaging in clinical practice. 99 
Material and Methods 100 
Details of consecutive patients undergoing surgical exploration for suspected PC between 101 
January 2006 and January 2014 were collected in a prospective database. Patients were 102 
offered surgery following review of imaging at a specialist HPB MDT and all scans were 103 
performed on 64-slice multi-detector CT (MDCT). Relevant abdominal CT scans were 104 
retrieved from referring hospitals, anonymised and uploaded to a dedicated research hard-105 
drive. Images were then re-reported independently by two radiologists with higher training in 106 
pancreatico-biliary imaging using standard criteria(14). The number of vascular contrast 107 
phases was recorded for each patient and the proportion of patients having mono, bi and tri-108 
phasic imaging in each of the referring hospitals was determined, along with the association 109 
of the number of scan phases with the main radiological findings. Specific data fields were 110 
created to collect information relating to hospital of origin, the presence of a biliary stent 111 
inserted at ERCP, tumour size, regional nodal status (presence of lymph nodes >1cm in 112 
transverse diameter) and vascular involvement status. Radiological evidence of arterial and 113 
venous involvement were defined according to published criteria (14) (Figure 1).  In the 114 
assessment of a binary variable (e.g. nodal status) a positive outcome was recorded only 115 
when both radiologists agreed on the finding. For tumour size the mean of the two findings 116 
was taken.  117 
At surgery initially a search for metastatic disease was undertaken before an attempt at 118 
dissection of the primary tumour. The tumour was considered to be unresectable due to local 119 
invasion when the operating surgeon was unable to resect the tumour after trial dissection 120 
without undertaking arterial resection or where there was occlusion or extensive invasion of 121 
the portal or superior mesenteric vein. Data retrieved from the database included the 122 
operative finding of either unexpected distant metastases or local invasion by tumour into 123 
vascular structures. The proportion of resectable tumours was recorded for consecutive 124 
quartiles (two year intervals) of the study period. To explore further the predictive value of 125 
radiological findings the operative outcome among patients where the tumours were found to 126 
be unresectable were categorised into the finding of metastatic disease or local invasion. 127 
Discrete variables and interdependence of radiological findings were analysed by Chi-square 128 
test and continuous variables by Mann-Whitney. Estimates of the relative value of 129 
radiological parameters in the prediction of resectability of PC were determined by logistic 130 
regression analysis. 131 
Ethical approval for the study was obtained from the South West Health Research Authority 132 
Research Ethics Committees. No patient consent was required for this study because patient 133 
data were collected in the course of normal hospital care and were anonymised for research 134 
purposes.  135 
The study is registered with ClinicalTrials.gov (unique identifier NCT02296736). 136 
 137 
 138 
Results  139 
Operative details and relevant pre-operative imaging were available in 409 patients (Figure 140 
2), of median age 66.9 (28-86) years, of whom 55.8% were male. The median age (66.7 v 141 
67.5 years), percentage of male patients (54.5% v 59.8%) and median interval between 142 
imaging and surgery (42 v 39 days, p=0.419) did not differ between patients proceeding to 143 
resection and those where the lesion was found to be unresectable. 144 
Analysis of images revealed a similar proportion of mono-, bi- and tri-phasic scans. There 145 
was variation in the number of vascular contrast phases undertaken in scans from different 146 
hospitals; however the rate of detection of the main radiological end-points did not differ 147 
according to the number of contrast phases undertaken (Table 1). In particular the proportion 148 
of patients noted to have AI did not differ between patients where only portal venous imaging 149 
was performed (3 of 134) and those where additional arterial phase imaging (bi- and tri-150 
phasic scans) was also performed (13 of 275) (p=0.223). The primary tumour was visible in 151 
250 patients (61.1%), with no difference in the rate of detection in patients having different 152 
contrast phase protocols (Table 1). Similarly the median tumour size was 26.7 (8-70) mm and 153 
did not differ between patients having different scan phases (p= 0.39). Where a tumour was 154 
visible RL, VI and AI were noted in 101 (40.4%), 47 (18.8%) and 16 (6.4%) of patients 155 
respectively. Among the 159 patients where no primary tumour was visible, RL was noted in 156 
40 (25%) patients. Tumour size was noted to be greater in patients with RL (28.5mm v 157 
26mm), AI (30.7mm v 26.5mm) and VI (33mm v 25.5mm) than in those without these 158 
findings (p= 0.02, 0.03 and 0.0001 respectively). In evaluation of interdependence of pre-159 
operative risk factors VI was noted to be strongly associated with AI (p=0.000). Of the 16 160 
patients with AI, 8 (50%) also were noted to have VI. The finding of RL was not significantly 161 
associated with either AI (p=0.472) or VI (p=0.108). 162 
Biliary stents had been inserted prior to CT scan in 73 (17.8%) patients. The proportion of 163 
patients with radiologically detectable RL did not differ between those who had (17/72, 164 
23.6%) and those who had not (84/337, 25%) had a stent inserted prior to CT scan (p=0.814).  165 
Surgical resection of the PC was completed in 292 patients (71.4%). Resection was 166 
completed more commonly among the 159 patients where no lesion was visible (126, 79%) 167 
than among the 250 patients where the tumour was visible (166, 66.4%) (p=0.005). Among 168 
the 155 patients with a visible tumour and no adverse risk factors (RL, AI or VI) on pre-169 
operative imaging, the median tumour size did not differ between the 121 patients where the 170 
tumour was resectable (24.5 mm, IQR 20.5-30.42) and the 34 patients where the tumour was 171 
not resectable (26.7mm, IQR 20-28.5mm) (p=0.55). 172 
Of the 17 patients with VI on pre-operative imaging where resection was completed, partial 173 
venous resection was necessary in three (17.6%) patients. Vein resection was also required in 174 
five of the 348 patients (1.4%) where VI was not noted pre-operatively.  175 
The final pathological diagnosis of resected specimens is shown in Table 2. 176 
In univariate analysis the presence of a visible tumour, tumour size, RL, AI and VI on pre-177 
operative imaging were all associated with unresectability of the tumour (Table 3). However 178 
in multivariate analysis the strongest association with tumour resectability was with the 179 
presence of AI (Table 3). Tumour size and VI were found to be mutually exclusive for 180 
significance in the multi-variate model.  181 
In the 117 patients where the tumour was not resected this was due to the finding of hepatic 182 
metastatic disease in 45 patients (37.8%) or local invasion of vascular structures in 72 183 
patients (60.5%). The proportion of patients with unresectable disease was 16/67 (23.8%), 184 
35/93 (37.6%), 32/119 (26.2%) and 34/130 (26.1%) (p=0.17) in consecutive time quartiles of 185 
the study. No difference was noted in the reasons for unresectability (local invasion or 186 
metastatic disease) among patients with different pre-operative radiological findings (Table 187 
4). 188 
 189 
Discussion 190 
This study allows the determination of a hierarchy of relative contraindications to resection of 191 
peri-ampullary cancer, based on a systematic assessment of radiological findings. In 192 
multivariable analysis the likelihood of completing surgical resection was reduced by a factor 193 
of 0.05, 0.31 and 0.51 by a finding of AI, VI and RL respectively, compared to a patient with 194 
none of these findings. In the absence of these findings tumour size was not associated with 195 
resectability. The study also revealed significant interdependence of radiological signs, with 196 
VI closely associated with tumour size (p<0.0001) and with AI (p=0.000). The study 197 
demonstrated that the proportion of patients with unresectable disease at the time of surgery 198 
has not declined over the eight year period of the study, and that the radiological findings are 199 
similar regardless of the number of scan phases undertaken. In addition pre-operative 200 
radiological findings were not able to predict the reason the pancreatic tumour was not 201 
resectable at the time of surgery (metastatic disease or local progression).  202 
Many studies have shown that AI and VI are risk factors for non-resection of pancreatic 203 
tumours (15-17). Most have focussed on assessing the accuracy of MDCT in identifying 204 
these risk factors in comparison with operative findings or histology (18-20). This study has 205 
used a structured reporting protocol to assess the relative risk that pre-operative identification 206 
of these findings entails for individual patients in terms of tumour resectability. AI is shown 207 
to be the most significant adverse finding, with a relative risk of resection of 0.05 compared 208 
to a patient without this finding. This may be due to the hepatic and superior mesenteric 209 
arteries lying further from the duodenal ampulla than venous structures, denoting a greater 210 
degree of invasion. The observation that the radiological findings of AI and VI are associated 211 
with each other may also reflect the spatial relationship of these structures, with VI occurring 212 
first followed by AI.  213 
The significance of radiological evidence of RL has been less well investigated previously. It 214 
is interesting to note that the presence of RL was not influenced by the insertion of biliary 215 
stents, so this finding should be attributed to a malignant, rather than inflammatory process. 216 
RL was also not associated with other signs of local tumour progression, and is only weakly 217 
associated with primary tumour size. The development of lymph node metastases in PC may 218 
therefore depend on different biological processes to primary tumour enlargement and local 219 
invasion. RL was however independently associated with tumour unresectability. This is 220 
probably due to this finding being a marker of a more aggressive malignancy. In a large 221 
proportion (69%) of patients with RL however the tumour remains resectable at surgery. 222 
Our study confirms that although tumour size is associated with invasion of vascular 223 
structures, size alone does not lead to an increased risk of non-resection in the absence of 224 
other adverse findings. This is significant as some centres have used tumour size alone as a 225 
factor in the decision to offer surgery for PC(8). 226 
The observation that 20% of patients with no detectable tumour radiologically are found to be 227 
inoperable at the time of surgery is an interesting finding. This suggests that although the 228 
interval from imaging to surgery has only a small impact on resectability in large series(21) 229 
there may be a more aggressive subset where progression proceeds rapidly. Similarly among 230 
the 271 patients where no adverse radiological signs were identified 54 (19.9%) were still 231 
found to be inoperable at the time of surgery. Caution must be exercised therefore in the 232 
interpretation of radiological findings when counselling patients. In addition although vein 233 
resection was required in 17.6% of patients undergoing resection where VI was noted on pre-234 
operative imaging it was also necessary in 1.4% of cases without VI on pre-operative 235 
imaging. These observations emphasize the limitations of pre-operative imaging in planning 236 
surgery for PC. 237 
The weaknesses of this study mainly relate to the non-standardised imaging protocols 238 
undertaken in different centres, and its retrospective nature. This study however represents an 239 
analysis of the value of pre-operative imaging in routine clinical practice, rather than under 240 
trial conditions, and the results are therefore likely to be relevant to other centres undertaking 241 
this type of surgery. Of particular interest is the finding that the radiological findings and 242 
resection rate are similar regardless of the number of contrast phases. Although multi-phase 243 
pancreatic–protocol CT is considered the ‘gold-standard’ in assessing resectability of PC(12), 244 
our results indicate that the resectability rate is unaltered by the CT technique used. It is 245 
possible that with a larger study the use of arterial phase contrast may lead to greater 246 
sensitivity in the detection of AI. This however does not seem necessary in patients with 247 
small tumours and no evidence of VI, where the risk of AI is very low. The study is also 248 
limited by the number of radiologists undertaking rereporting (two). The agreement between 249 
radiologists is being addressed seperately and it is possible that the results have been biased 250 
by individual radiologists performance.  251 
The analysis of surgical outcomes has revealed the most common cause for non-resection 252 
was invasion of vascular structures (60.5%), with metastatic disease a less common finding 253 
(37.8%). Patients noted to have AI or VI on pre-operative imaging had a similar likelihood of 254 
being inoperable due to metastatic disease or local invasion at the time of surgery, suggesting 255 
that these findings are markers of aggressive malignancy. CT has a high resolution for 256 
hepatic metastases, which has increased in recent years(22). Despite this the proportion of 257 
patients with unresectable disease has remained largely unchanged over the period of study. 258 
This finding suggests that disease progression between imaging and the time of surgery may 259 
be a more significant cause of inoperability than understaging by CT. There may therefore be 260 
an irreducible number of patients with rapidly progressive disease who will be unresectable at 261 
the time of surgery, regardless of the quality of the imaging and reporting undertaken.  262 
The strength of this study lies in its large size and in the assessment of imaging of 263 
heterogeneous technique from different hospitals. Other studies have shown similar risk 264 
factors for non-resection(23, 24), and a similar rate of non-resection (23, 24) at the time of 265 
surgery, and there is little available evidence that this rate has declined with improved 266 
imaging. This may be due to alterations in the threshold for undertaking surgery in borderline 267 
cases and improvements in surgical technique. The study however reveals significant 268 
limitations in the ability of MDCT to predict the presence of surgically significant operative 269 
findings. 270 
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Number of patients 
n= 421 
Scan reviewed 
n= 411 
Non-resectable disease 
n= 117 (28.6%) 
No scan available  
n= 10 
Locally advanced 
disease 
n= 72 (61.5% ) 
Metastatic disease 
n= 45 (38.5% ) 
 
Resectable disease 
n= 292 (71.4%) 
Exclusions 
One patient surgically 
unfit 
One patient with 
pancreatitis at surgery 
with no visible mass  
n = 409 
Monophasic 
(134, 32.7%) 
Biphasic 
(149, 36.4%) 
Triphasic 
(126, 31%) 
P 
Hospital 
A (119) 20 (16.8) 52 (43.7) 46 (38.6) 
0.0001 
B (97) 45 (46.4) 50 (51.5) 2 (2.1) 
C (78) 24 (30.7) 9 (11.5) 45 (57.7) 
D (71) 24 (33.8) 21(29.5) 26 (36.6) 
E (44) 21 (47.7) 17 (38.6) 6 (13.6) 
AI (16) 3 (2.4) 8 (5.4) 5 (4) 0.398 
VI (47) 20 (15) 11 (7.4) 16 (12.7) 0.122 
RL (101) 28 (21) 42 (28.2) 31 (24.6) 0.83 
Tumour visible (250) 72 (53.7) 99 (66.4) 79 (62.7) 0.83 
Median tumour size 
(average) 
25.25 
(11.5-70) 
26.25 
(10.5-58) 
27.75 
(8-64.5) 
0.39 
Resection completed 
(292) 
102 (76.1) 107 (71.8) 83 (65.8) 0.187 
 397 
Table 1. Radiological findings and surgical resection rate according to the number of CT scan 398 
phases for 409 patients undergoing attempted surgical resection for PC 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
Tumour origin N (%) Median tumour size 
(range) mm 
Histological lymph 
node involvement 
(%) 
Pancreatic adenocarcinoma 132 (45.2) 30 (12-65) 122 (92.4) 
Ampullary adenocarcinoma 66 (22.6) 25 (5-80) 37 (56) 
Bile duct adenocarcinoma 47 (16.1) 25 (10-70) 25 (53.2) 
Duodenal adenocarcinoma 7 (2.4) 40 (30-55) 4 (47) 
Tubulo-villous adenoma 15 (5.1) 30 (24-55)  
Inflammatory disease 12 (4.1)   
Neuroendocrine tumour 6 (2) 18 (10-25) 3 (50) 
Metastasis 4 (1.4) 35 (25-45)  
Gastro Intestinal Stromal cell 
tumour (GIST) 
1 (0.03)  0 (0) 
Others (Benign) 2 (0.6)   
 409 
Table 2. Histological outcome of 292 patients undergoing surgical resection for presumed 410 
PC. 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
Imaging 
characteristic 
Tumour resectability UVA MVA 
Yes 
(292) 
No 
(117) 
p Exponent 
95% CI of 
Exponent 
p 
Median 
tumour size 
(mm)(range) 
25.5 
(8-70) 
28 
(11.5-64.5) 
 
0.01 
 
0.46 
 
(0.193-1.084) 
 
0.076 
RL (101) 
(%) 
63 
(21.6) 
39 
(32.8) 
 
0.017 
 
0.51 
 
(0.272-0.949) 
 
0.047 
AI (16) 
(%) 
2 
(0.68) 
14 
(11.7) 
 
0.000 
 
0.05 
 
(0.007-0.445) 
 
0.007 
VI (47) 
(%) 
17 
(5.82) 
30 
(25.2) 
 
0.000 
 
0.31 
 
(0.152-0.638) 
 
0.001 
 420 
Table 3. Univariate and multivariate analysis of the association of the preoperative 421 
radiological risk factors and surgical resectability of PC in 409 patients 422 
 423 
 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
n=117 Local 
progression 
(n= 72) 
Metastatic 
disease 
(n= 45) 
Chi 
Sq 
P 
Radiological finding 
Tumour visible (84, 71.8%) 
49 
(58.3) 
35 
(41.6) 
1.3 0.256 
Median tumour size (mm)  
(range) 
28.25 
(11.5-64.5) 
27.75 
(16.5-55.5) 
 
0.838 
 
0.36 
RL (38, 32.5%) 23 (60.5) 15 (39.5) 0.024 0.876 
AI (16, 13.7%) 9 (56.2) 5 (31.25) 0.051 0.822 
VI (30, 25.6%) 22 (73.3) 8 (26.6) 2.37 0.123 
No adverse radiological findings 
(54, 46.1%) 
32 (59.2) 22 (40.7) 0.22 0.639 
 435 
Table 4. Reasons for non-resection (local invasion or metastatic disease) among 117 patients 436 
undergoing attempted surgical resection for PC with different pre-operative radiological 437 
findings 438 
 439 
 440 
 441 
 442 
 443 
